PMID- 32304562
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20210113
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 76
IP  - 1
DP  - 2020 Jul
TI  - Effect of High Homocysteine Level on the Severity of Coronary Heart Disease and 
      Prognosis After Stent Implantation.
PG  - 101-105
LID - 10.1097/FJC.0000000000000829 [doi]
AB  - OBJECTIVES: To determine the effect of high homocysteine (HCY) levels on the 
      severity of coronary artery disease and prognosis after stent implantation. 
      METHODS: A prospective study was conducted on 667 patients with coronary heart 
      disease who underwent drug-eluting stent implantation for the first time at the 
      Department of Cardiology, Huludao Central Hospital, from January 2015 to December 
      2017. The patients were divided into the control and hyperhomocysteinemia (H-HCY) 
      groups based on the serum HCY levels. The demographic and clinical 
      characteristics of both groups were compared. In addition, the patients were 
      followed up for 1 year to compare the incidence of major adverse cardiovascular 
      and cerebrovascular events (MACCE). Multivariate logistic regression was used to 
      determine the correlation between serum HCY levels and MACCE. RESULTS: Compared 
      with the control group, the stenosis degree was significantly higher among 
      patients in the H-Hcy group, as indicated by more coronary artery lesions (P < 
      0.001) and higher SYNTAX scores (P < 0.001). After 1 year of follow-up, the 
      incidence of MACCE was also significantly higher in the H-HCY versus control 
      group (9.5% vs. 15.1%; P = 0.042). Furthermore, age, history of diabetes, 
      discontinuation of antiplatelet aggregation drugs, and HCY levels were 
      independent predictors of MACCE. CONCLUSIONS: High HCY level is associated with 
      severe coronary artery disease in patients with coronary heart disease and is an 
      independent predictor of MACCE after stent implantation.
FAU - Li, Shanshan
AU  - Li S
FAU - Sun, Liping
AU  - Sun L
AD  - Cardiology.
FAU - Qi, Liqun
AU  - Qi L
AD  - Infection Management, Huludao Center Hospital, Huludao, Liaoning, People's 
      Republic of China and.
FAU - Jia, Yongsheng
AU  - Jia Y
AD  - Cardiology.
FAU - Cui, Zhuo
AU  - Cui Z
AD  - Department of Scientific Education, Huludao Center Hospital, Huludao, Liaoning, 
      People's Republic of China.
FAU - Wang, Zhongsuo
AU  - Wang Z
FAU - Li, Fengshuai
AU  - Li F
AD  - Cardiology.
FAU - Zhao, Xiaofeng
AU  - Zhao X
AD  - Cardiology.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Biomarkers)
RN  - 0LVT1QZ0BA (Homocysteine)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Coronary Artery Disease/complications/diagnostic imaging/*therapy
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Homocysteine/*blood
MH  - Humans
MH  - Hyperhomocysteinemia/*blood/complications/diagnosis
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/adverse effects/*instrumentation
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2020/04/19 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/04/19 06:00
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
PHST- 2020/04/19 06:00 [entrez]
AID - 10.1097/FJC.0000000000000829 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2020 Jul;76(1):101-105. doi: 
      10.1097/FJC.0000000000000829.